AKT1 and urinary bladder cancer: We demonstrated that combination therapy with an AKT inhibitor (AZD5363) and an mTOR inhibitor (AZD2014 or BEZ235) exerted a synergistic effect on the viability and colony formation ability of bladder cancer cells carrying PI3KCA and mTOR mutations.